Penn Medicine and CHOP: $25 Million Gift to Establish Center for Epilepsy and Neurodevelopmental Disorders

A $25 million gift from an anonymous donor to Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will establish the Center for Epilepsy and Neurodevelopmental Disorders (ENDD), accelerating collaborative research in genetic therapies for neurodevelopmental disorders. This gift will bolster the efforts of an interdisciplinary group of clinicians and scientists at Penn and CHOP, led by director Benjamin Prosser and co-directors Beverly Davidson and Ingo Helbig. Dr. Prosser is an associate professor of physiology at the University of Pennsylvania’s Perelman School of Medicine. He adjusted the focus of his research career when his daughter, Lucy, was diagnosed shortly after birth in 2018 with a rare genetic neurodevelopmental disorder.
“ENDD offers hope to patients and families living with the many challenges of rare, genetic neurodevelopmental disorders,” said J. Larry Jameson, executive vice president of the University of Pennsylvania for the health system and dean of the Perelman School of Medicine. “This important gift will accelerate the progress of an extraordinary partnership between Penn and CHOP that demonstrates the power of collaboration and a commitment to finding cures. We are incredibly grateful to this donor, whose dedication to the advancement of research in this area is sure to create the launch pad for a new outlook for those diagnosed with these conditions.”
The gift was made in honor of the late television executive Daniel B. Burke, whose son Stephen B. Burke served on the board of trustees at CHOP.
“We are extremely grateful for this visionary gift that supports our efforts to solve the unsolvable when it comes to rare diseases, improving our ability to translate new discoveries about potential therapies into clinical practice,” said Madeline Bell, president and CEO of Children’s Hospital of Philadelphia. “CHOP and Penn have systematically invested in integrated care programs for genetic epilepsies and neurodevelopmental disorders. This new center will fill the gap between the tremendous advances in early diagnosis and comprehensive clinical care and the development of new treatments for these patients.”
ENDD will initially focus on developing therapies for disorders related to mutations of the STXBP1 and SYNGAP1 genes—which are linked to abnormal brain function, intellectual disability, epilepsy, and motor and behavioral impairments—with the goal of expanding its efforts to other genetic neurodevelopmental disorders over time. ENDD strengthens an existing partnership between Dr. Prosser and Dr. Davidson, the director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, chief scientific strategy officer at CHOP, and a professor of pathology and lab medicine at Penn, and Dr. Helbig, a pediatric neurologist in the department of neurology at Penn and in the division of neurology at CHOP and the director of genomic science at CHOP’s Epilepsy Neurogenetics Initiative (ENGIN). Their joint work in the center will target the development of antisense oligonucleotide (ASO), gene therapy, and CRISPR-based strategies for the treatment of NDD.
Dr. Prosser’s daughter Lucy was diagnosed with a rare, genetic neurodevelopmental disorder caused by a mutation of the STXBP1 gene. STXBP1-related disorders cause a range of symptoms, including seizures, developmental delays, intellectual disabilities, and movement disorders. There is no known cure or effective treatment.
Driven by a desire to help his daughter and the more than 5,000 children with STXBP1 disorders born each year worldwide, Dr. Prosser, an expert in cardiac molecular biology, launched a separate research arm in his lab focused on developing new therapies for STXBP1 and related disorders. He began collaborating with Drs. Davidson and Helbig, as well as other researchers and clinicians across Penn and CHOP, forming the ENDD Therapeutics Team.
“As a scientist and as a parent, I am incredibly grateful for this gift, which will propel our work forward with the hope of changing the course of these disorders,” Dr. Prosser said. “We have a rare opportunity with such a brilliant and dedicated team of scientists and clinicians at Penn and CHOP, who are motivated each day to make a difference for Lucy and children like her.”
Dr. Davidson, a world-renowned expert on gene therapy in neurological disorders, works to understand the molecular basis of childhood onset neurodegenerative diseases and the development of gene and small molecule therapies for treatment. Dr. Helbig, who serves as one of the directors of the Epilepsy Neurogenetics Initiative at CHOP, has particular expertise in SYNGAP1 and STXBP1 and treats many children with these disorders, including Lucy Prosser. This unique combination of clinical knowledge, innovation in gene therapy, and the drive of a parent-scientist will accelerate the development of new therapies for neurodevelopmental disorders.




“This new partnership places Penn Dental Medicine at the center of the oral health-evidence-synthesis field globally and aligns with the school’s mission to transform global oral health and well-being through exceptional clinical care, innovation, education, and research,” said Alonso Carrasco-Labra, director of the Cochrane Oral Health Collaborating Center and an associate professor in the department of preventive & restorative sciences at Penn Dental Medicine.
Geraldine (Gerri) Shnakis Paier, Nu’68, GNu’85, GrN’94, a member of the boards of the Penn Museum and of Penn’s School of Nursing, died on December 24, 2022, from complications of a stroke. She was 79.
Stanley Sidney Schor, C’43, G’50, PhD’52, a former associate professor of statistics, economics, and public health and preventive medicine in Penn’s School of Arts and Sciences, died on December 26, 2022 of vascular dementia. He was 100.
Kimberly Bowes, a professor of classical studies in the School of Arts and Sciences, has won the 2023 Anna Marguerite McCann Award for Fieldwork Reports from the Archaeological Institute of America for her two-volume work, The Roman Peasant Project 2009-2014: Excavating the Roman Rural Poor. The Anna Marguerite McCann Award recognizes an outstanding monograph presenting results from an archaeological field project.


César de la Fuente, the Presidential Assistant Professor of psychiatry, microbiology, chemical and biomolecular engineering, and bioengineering, has been selected to receive the American Peptide Society’s 2023 Rao Makineni Lectureship Award. This award was established in 2003 and recognizes an individual who has made a recent contribution of unusual merit to research in the field of peptide science. This award will be presented in June during the 28th American Peptide Society Symposium in Scottsdale, Arizona, where Dr. de la Fuente will present a special lecture.
Paul J. Mather, a professor of clinical medicine and the physician leader of heart failure disease management, has been honored with the American Heart Association’s (AHA) 2023 Edward S. Cooper, MD Award. Dr. Mather has been a dedicated volunteer for the AHA, serving in leadership roles as local board president in Greater Philadelphia and regional board president for the former Great Rivers Affiliate. His passion and commitment to the AHA are exemplified through his previous awards, including the Dr. Lynn A. Smaha Memorial Award of Excellence in 2019 and the AHA National Physician of the Year Award in 2020.
Jessica I. W. Morgan, an associate professor of ophthalmology, has received the 2023 Pfizer Ophthalmics Carl Camras Translational Research Award of the Association for Research in Vision and Ophthalmology. The $12,000 award is granted to early career investigators working in areas of translational research whose work has promise of leading to clinical application. Dr. Morgan applies high-resolution retinal imaging techniques to study the structure and function of the retina at the cellular level, enabling researchers to investigate the pathogenesis and treatment of retinal disease.
John Wierzbowski, corporate manager of enterprise business continuity and emergency operations, has received the COVID-19 Pandemic Civilian Service Medal for exemplary service to the nation as part of the federal medical response to the pandemic. Mr. Wierzbowski serves as a member of the Incident Management Team (IMT) in the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response. Mr. Wierzbowski is one of approximately 90 IMT responders to receive the award for civilians who deployed for 30 consecutive or 60 cumulative days to provide medical care to state, territory, tribal, and local partners. He also serves as the chair of the Southeast Regional (Pennsylvania) Healthcare Coalition and as a member of the federal healthcare and public health sector coordinating council.